[Susceptibilities of clinical isolates to antibacterial agents. Focusing mainly on ofloxacin (first report). Reported by the Research Group for Testing Ofloxacin Susceptibility of Clinical Isolates].

Susceptibility tests were carried out on a variety of clinically isolated pathogens using the susceptibility disc method at 197 hospitals in Japan between May, 1985 through March, 1986. These tests were organized by the Research Group for Testing Ofloxacin Susceptibility on Clinical Isolates, and the results were statistically analyzed. This paper describes a comparison of susceptibilities of clinical isolates including Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Streptococcus pneumoniae, Neisseria gonorrhoeae, Escherichia coli, Enterobacter aerogenes, Enterobacter cloacae, Citrobacter freundii, Klebsiella pneumoniae subsp. pneumoniae, Proteus mirabilis, Morganella morganii, Serratia marcescens, Haemophilus influenzae, Pseudomonas aeruginosa, Acinetobacter calcoaceticus, Acinetobacter sp. and Campylobacter jejuni to ofloxacin (OFLX) and conventional antibacterial drugs. The results obtained were summarized as follows. 1. OFLX showed strong antibacterial activity against S. aureus, S. epidermidis, N. gonorrhoeae, E. coli, E. aerogenes, E. cloacae, C. freundii, K. pneumoniae subsp. pneumoniae, P. mirabilis, M. morganii, H. influenzae, A. calcoaceticus, Acinetobacter sp. and C. jejuni and only a few strains were resistant to OFLX. Moreover, OFLX has superior antibacterial activity against many species compared not only to norfloxacin but also to most of the conventional antibacterial drugs. 2. When studied by sampled materials such as sputum, urine, abscesses and otorrhea, OFLX occasionally showed different actions against the same species from different sources. Almost species from the urinary isolates were less sensitive than those from the sputum.